Approved Study Database
| Ref. No. | Scientific Title | Principal investigator |
|---|---|---|
| 2017.356 | China local BRCA testing and exploration of ovarian cancer treatment outcomes of different BRCA status in newly diagnosed epithelial ovarian cancer patients |
Prof. YEO Winnie 楊明明 |
| 2015.184 | A 60-m prospective study of long-term intake of dietary isoflavones and lignans on the risk of recurrence and mortality in Chinese women with early-stage breast cancer | Prof. YEO Winnie |
| 2016.010 | Cancer Health Literacy among Chinese cancer patients in Hong Kong | Prof. YEO Winnie |
| 2016.435 | A prospective study of circulating and urinary isoflavones and lignans concentration at 60-m after diagnosis and the risk of recurrence and mortality in Chinese women with early-stage breast cancer | Prof. YEO Winnie |
| 2016.156 | RETROSPECTIVE REVIEW OF TUMOUR CHARACTERISTICS AND OUTCOMES OF BREAST CANCER PATIENTS |
Prof. YEO Winnie 楊明明 |
| 2025.159 | Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer with High Risk of Recurrence—A Global, Multicenter, Randomized, Open-label Phase 3 Study (ELEGANT) | Prof. YEO Winnie |
| 2024.137 | A Phase 3, Multicenter, Open-label, Randomized Study to Compare the Efficacy and Safety of MK-2870 Versus Treatment of Physician’s Choice in 3L+ Advanced/Metastatic Gastroesophageal Adenocarcinoma (Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, and Esophageal Adenocarcinoma) | Prof. YEO Winnie |
| 2024.342 | A Phase III Multi-center, Open-label, Sponsor-blinded, Randomized Study of AZD0901 Monotherapy Compared with Investigator’s Choice of Therapy in Second- or Later-Line Adult Participants with Advanced/Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2 (CLARITY-Gastric 01) | Prof. YEO Winnie |
| 2024.409 | A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy | Prof. YEO Winnie |
| 2024.096 | An Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination with Pembrolizumab Versus Treatment of Physician’s Choice in Participants with HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer | Prof. YEO Winnie |
| 2008.294 | A Multicenter Phase III Randomized Trial of Adjuvant Therapy for Patients with HER2-Positive Node-Positive or High Risk Node-Negative Breast Cancer Comparing Chemotherapy Plus Trastuzumab with Chemotherapy Plus Trastuzumab Plus Bevacizumab | Prof Yeo Winnie |
| 2011.467 | PROACTYVE pilot: Pilot study of Patient | Prof Yeo Winnie |
| 2009.444 | A Phase III randomized, placebo controlled, double blind trial of Sorafenib plus Erlotinib vs. Sorafenib plus placebo as First Line systemic treatment for Hepatocellular Carcinoma (HCC) | Prof. Yeo Winnie |
| 2007.095 | Phase I/II Study of Paclitaxel/ Carboplatin/ RAD001 as First Line Therapy for Advanced Adenocarcinoma of the Stomach | Prof. YEO Winnie |
| 2008.284 | Premature Postmenopausal Symptoms Affecting the Quality of Life of Younger Breast Cancer Survivors in Hong Kong | Prof. YEO Winnie |
| 2010.235 | Prospective study of soy intake and breast cancer prognosis in Chinese breast cancer survivors | Prof. YEO Winnie |
| 2008.235 | A Multinational, Randomized, Open-Label, Phase 3 Study of Sunitinib Malate versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma | Professor Yeo Winnie |
| 2010.422 | A Phase II trial of BAY 86-9766 plus sorafenib as a first line systemic treatment for hepatocellular carcinoma (HCC) | Prof. Yeo Winnie |
| 2008.395 | Phase I/II Study of Temsirolimus (Torisel) as Novel Therapeutic Drug for Patients with Unresectable Hepatocellular Carcinoma (HCC) - A Correlative Study with Stathmin Over-expression | Prof. YEO Winnie |
| 2009.360 | A randomised Phase III clinical study of bevacizumab plus capecitabine vs. bevacizumab alone as maintenance therapy in patients with HER2-negative metastatic breast cancer that has not progressed during first-line docetaxel plus bevacizumab therapy | Prof. YEO Winnie |
| 2009.376 | A Randomized, Double-blind, Multi-centre Phase III Study of Brivanib versus Sorafenib as First-line Treatment in Patients with Advanced Hepatocellular Carcinoma: The BRISK FL Study | Professor Yeo Winnie |
| 9406(S) | A Prospective Randomized Phase III Study Comparing the Combination of Cisplatin, Doxorubicin, Interferon-Alpha-2B and 5-Fluorouracil to Doxorubicin Alone in the Treatment of Inoperable Hepatocellular Carcinoma | Prof. YEO Winnie |
| 2013.088 | A Phase 1/2, Dose-escalation, Open-label, Non-comparative Study of Nivolumab or Nivolumab in Combination with Ipilimumab in Advanced Hepatocellular Carcinoma Subjects with or without Chronic Viral Hepatitis; and a Randomized, Open-label Study of Nivolumab vs Sorafenib in Advanced Hepatocellular Carcinoma Subjects who are Naive to Systemic Therapy | Prof. YEO Winnie |
| 2006.340 | Predictors of Survival in Patients with Unresectable Hepatocellular Carcinoma-Clinical, Quality of Life and Virological Factors | Prof. YEO Winnie |
| 2009.202 | A Randomized, Double-blind, Multi-center Phase III Study of Brivanib plus Best Supportive Care (BSC) versus Placebo plus BSC in Subjects with Advanced Hepatocellular Carcinoma (HCC) who have Failed or are Intolerant to Sorafenib | Professor Yeo Winnie |
| 2012.472 | A Two-Cohort, Open-Label, Multicenter, Study of Trastuzumab Emtansine (T-DM1) in HER2 Positive Locally Advanced or Metastatic Breast Cancer Patients who have Received Prior Anti-HER2 and Chemotherapy-Based Treatment | Prof. YEO Winnie |
| 2013.427 | A prospective, single-arm, multicenter, uncontrolled, open-label Phase II trial of refametinib (BAY 86-9766) in patients with RAS mutant Hepatocellular Carcinoma(HCC) | Prof Yeo Winnie |
| 2002.230 | "HERA: A Randomized Three-arm Multi-centre Comparison of 1 Year and 2 Years of Herceptin Versus No Herceptin in Women with HER2-positive Primary Breast Cancer Who Have Completed Adjuvant Chemotherapy" | Prof. YEO Winnie |
| 2012.145 | A PHASE III PROSPECTIVE, TWO-COHORT NON-RANDOMIZED, MULTI-CENTRE, MULTINATIONAL, OPEN LABEL STUDY TO ASSESS THE SAFETY OF ASSISTED- AND SELF-ADMINISTERED SUBCUTANEOUS TRASTUZUMAB AS THERAPY IN PATIENTS WITH OPERABLE HER2-POSITIVE EARLY BREAST CANCER [SafeHer Study] | Prof. YEO Winnie |
| 2010.201 | An Open-label, Randomized Phase 3 Study of Efficacy and Tolerability of Linifanib (ABT-869) versus Sorafenib in Subjects with Advanced Hepatocellular Carcinoma (HCC) | Prof. Yeo Winnie |
| 2010.601 | LUX-Breast 2: An open label, phase II trial of BIBW 2992 (afatinib) in patients with metastatic HER2-overexpressing breast cancer failing HER2-targeted treatment in the neoadjuvant and/or adjuvant treatment setting | Prof. YEO Winnie |
| 2023.267 | A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Patients With Hormone Receptor-Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2−) (HER2 IHC0 or HER2-low [IHC 1+, IHC 2+/ISH−]) Inoperable, Locally Advanced, or Metastatic Breast Cancer and Have Received Endocrine Therapy | Prof. YEO Winnie |
| 2022.173 | EPIK-B3: A Phase III, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with nab-paclitaxel in patients with advanced triple negative breast cancer with either phosphoinositide-3-kinase catalytic subunit alpha (PIK3CA) mutation or phosphatase and tensin homolog protein (PTEN) loss without PIK3CA mutation |
Prof. YEO Winnie 楊明明教授 |
| 2023.269 | A phase IIIb study to characterize the effectiveness and safety of Adjuvant ribociclib in a wide patient population with HR+ HER2-early breast cancer (Adjuvant WIDER) | Prof. YEO Winnie |
| 2020.653 | A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Lenvatinib (E7080/MK-7902) plus Pembrolizumab (MK-3475) plus Chemotherapy Compared with Standard of Care Therapy as First-line Intervention in Participants with Advanced/Metastatic Gastroesophageal Adenocarcinoma (LEAP-015) |
Prof. YEO Winnie 楊明明教授 |
| 2022.510 | A Multinational, Multicenter, Non-Interventional, Retrospective, Observational, Real-World Study: Treatment Patterns in Patients with HER2-Positive Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma in East Asia (HER2+ GASTA Study) |
Prof. YEO Winnie 楊明明 |
| 2021.219 | A Phase 3, Multicenter, 2-Arm Randomized, Open-Label Study of Trastuzumab Deruxtecan in Subjects with HER2-Positive Metastatic and/or Unresectable Gastric or Gastro-Esophageal Junction (GEJ) Adenocarcinoma Subjects who have Progressed on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04) |
Prof. YEO Winnie 楊明明教授 |
| 2022.286 | A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced, Inoperable, or Metastatic Triple-Negative Breast Cancer, Whose Tumors Express PD-L1 |
Prof. YEO Winnie 楊明明教授 |
| 2021.563 | A Phase 2 Study of Magrolimab Combination Therapy in Patients With Unresectable, Locally Advanced or Metastatic Triple-Negative Breast Cancer |
Prof. YEO Winnie 楊明明教授 |
| 2022.285 | A Phase 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpression (FORTITUDE-102) |
Prof. YEO Winnie 楊明明 |
| 2021.162 | A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in Subjects with High-Risk HER2-Positive Primary Breast Cancer Who Have Residual Invasive Disease in Breast or Axillary Lymph Nodes Following Neoadjuvant Therapy |
Prof. YEO Winnie 楊明明教授 |
| 2023.629 | A Phase 3, Randomized, Multi-center, Open-label Study of DB-1303 Versus Investigator’s Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low, Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) | Prof. YEO Winnie |
| 1995.526 | Randomized Trial of High-Dose Epirubicin and Cyclophamide x 3 Supported by Peripheral Blood Projector Cells Versus Anthracycline and Cyclophosphamide x 4 Followed by Cyclophosphamide, Methotrexate & 5- Fluorouracil as Adjuvant Treatment for High Risk Operable Stage II and Stage III Breast Cancer in Premenopausal and Young Postmenopausal (<65 yrs) Patients | Prof. YEO Winnie |
| 2010.326 | A longitudinal study of psychosocial needs and psychological distress of Chinese women with advanced breast cancer: A follow-up study | Prof. YEO Winnie |
| 2012.158 | Design Innovation and Customisation of the Mastectomy Bra and Prosthesis for Hong Kong Mastectomy Patients: A Multidisciplinary Approach | Prof. YEO Winnie |
| 2013.417 | GASTRIC CANCER PATIENTS RECEIVING ADJUVANT TS-1- A SURVEY ON PATIENTS’ TOLERABILITY | Prof. YEO Winnie |
| 2009.158 | Effect of Genetic Polymorphisms and Gene Expression in Chemotherapy-Related Toxicities in Chinese Breast Cancer Patients | Prof Yeo Winnie |
| 2010.204 | Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B treated with anti-B cell therapy-Effective and Cost-Effectiveness of prevention | Prof. Yeo Winnie |
| 2011.196 | Quality of life of Chinese patients with hepatocellular carcinoma and its value as prognosticator for the disease | Prof Yeo Winnie |
| 2009.077 | Clinical Application of Genetic Markers in Prediction of Doxorubicin and Taxane Induced Cytotoxicity in Mammary Cancer Patients of Asian Ethnicity | Prof Yeo Winnie |
Page 252 of 265.